Chicago Nurse Accused of Distributing Counterfeit Ozempic

A registered nurse in Chicago is under federal charges for handing out counterfeit versions of the weight-loss medication Ozempic. The drugs, which did not contain the key component semaglutide, were allegedly distributed to three people. She has pleaded not guilty and faces potential jail time.

Authorities claim the medications originated from sources other than Ozempic's producer and lacked the medication's essential active substance.

CHICAGO - A healthcare professional from Chicago stands accused of administering bogus Ozempic, the widely used weight-reduction treatment.

What We Know

Government prosecutors allege that Sharon Christine Sackman supplied imitation Ozempic to three individuals in Chicago during 2023.

Court documents indicate that although the vials bore Ozempic branding, they were not produced by Novo Nordisk, the pharmaceutical firm responsible for the original drug, and omitted semaglutide, its primary active element.

Prosecutors explained that Sackman functioned as a licensed practical nurse at the moment of the distribution but lacked authorization to prescribe, provide, dispense, or sell Ozempic.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

She faces one accusation of circulating improperly labeled medications and three charges of issuing fake pharmaceuticals. Each offense could result in a maximum federal imprisonment term of one year.

During her appearance in a Chicago federal courtroom on Tuesday, she entered a not guilty plea.

Authorities mentioned that Sackman, aged 52, presently resides in Playa del Carmen, Mexico.

What's Next

A court session to review the case's progress is set for February 3.

Health tracking apps like Shotlee can assist users in monitoring medication authenticity and side effects during weight management journeys.

Source Information

Originally published by FOX 32 Chicago.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Counterfeit medications

All Counterfeit medications articles →

Medication Safety

Ozempic Safety: How to Verify Batch Numbers and Avoid Counterfeit Drugs

With the surge in demand for weight loss and diabetes medications, counterfeit drugs have become a critical safety concern. This guide details how to verify Ozempic batch numbers and protect your health.

7 min read

Health & Wellness

Oral GLP-1 Drugs: A New Era for Weight Management in India

The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.

7 min read

GLP-1 Medications Safety

Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities

Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.

5 min read

More in Health

Health

Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter

Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.

8 min read

Health

Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss

Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.

8 min read

Health

Exploring 'Natural Ozempic' and Assessing the Strength of Its Scientific Foundation

With slimming injections gaining immense popularity, curiosity rises about a potential natural substitute known as 'natural Ozempic,' a supplement aimed at boosting hormones to curb appetite. While it draws from oils to mimic effects similar to GLP-1, scientists debate its maturity and real-world impact. This piece delves into the supporting evidence, expert critiques, and comparisons with established medications.

4 min read